Dr Martin Kaiser’s Team aims to design gentler, tailored therapies for patients with multiple myeloma, an immune cell cancer of the bone marrow.
Dr Martin Kaiser is the team leader of the Myeloma Molecular Therapy group at the ICR and Honorary Consultant Haematologist at The Royal Marsden NHS Foundation Trust.
I joined the team in December 2020 and I am involved in the bio-banking of samples from national myeloma clinical trials. I use flow cytometry and a variety of molecular biology techniques to assess molecular profiles and genetic aberrations in patients with multiple myeloma.